Dermata Therapeutics, Inc. (NASDAQ:DRMA) Short Interest Up 1,812.1% in December

by · The Markets Daily

Dermata Therapeutics, Inc. (NASDAQ:DRMA – Get Free Report) was the recipient of a large growth in short interest during the month of December. As of December 31st, there was short interest totaling 752,424 shares, a growth of 1,812.1% from the December 15th total of 39,351 shares. Approximately 90.0% of the company’s stock are short sold. Based on an average daily volume of 4,189,295 shares, the days-to-cover ratio is currently 0.2 days. Based on an average daily volume of 4,189,295 shares, the days-to-cover ratio is currently 0.2 days. Approximately 90.0% of the company’s stock are short sold.

Dermata Therapeutics Stock Performance

Dermata Therapeutics stock opened at $2.12 on Wednesday. The stock has a market cap of $2.18 million, a PE ratio of -0.27 and a beta of 0.54. The stock has a 50-day moving average of $2.59 and a two-hundred day moving average of $4.52. Dermata Therapeutics has a one year low of $1.58 and a one year high of $23.70.

Dermata Therapeutics (NASDAQ:DRMA – Get Free Report) last posted its quarterly earnings data on Friday, November 14th. The company reported ($1.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.59) by ($0.06).

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e)” rating on shares of Dermata Therapeutics in a report on Monday, December 29th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $10.00.

View Our Latest Research Report on Dermata Therapeutics

About Dermata Therapeutics

(Get Free Report)

Dermata Therapeutics is a clinical-stage immunodermatology company dedicated to developing novel small-molecule therapies for inflammatory skin disorders. The company’s lead clinical candidate, DMVT-502, is being evaluated in atopic dermatitis, while DMVT-505 is in development for vitiligo. In addition to these programs, Dermata advances preclinical assets targeting other indications such as alopecia areata.

At the core of Dermata’s approach is a proprietary drug discovery platform that combines structure-based design, medicinal chemistry and innovative formulation techniques.

Further Reading